JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer
Recruiting · NCT04951947 · Interventional (participants receive a specific treatment) · Lead sponsor: Hunan Province Tumor Hospital
View the official record on ClinicalTrials.gov →Interventions studied
JS201 combine with Lenvatinib
What this trial is about
This is a prospective, single-arm phase II clinical study to evaluate the efficacy and safety of JS-201 combined with lenvatinib in the treatment of small-cell lung cancer that has failed previous chemotherapy combined with PD-L1. The primary observational endpoint is ORR, and the secondary observational endpoint is PFS, OS. The intervention mode is JS201 300mg i.v Q2w, lenvatinib 8mg po. Qd.
Who can take part
Age range
18 Years to 75 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Phase 2
Study type
Interventional (participants receive a specific treatment)
Inclusion criteria
- 1\. The imaging diagnosis is the extensive stage of SCLC
- 2\. The patient failed first-line EC+PD-L1 treatment
- 3 PS 0-1
Exclusion criteria
- 1\. Diagnosed as non-small cell lung cancer
- 2\. Women during pregnancy
- 3\. Patients with symptomatic brain metastases
- 4\. PS≥2
Where it is running
1 location listed.
- Hunan Cancer Hospital - Changsha, Hunan, China